Literature DB >> 27827307

Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD.

Margaret K Yu1, Sun H Kim2.   

Abstract

Entities:  

Keywords:  Chronic; Diabetes Mellitus; Kidney Failure; Renal Insufficiency; Type 2; diabetic nephropathy

Mesh：

Substances：

Year:  2016        PMID： 27827307      PMCID： PMC5142075          DOI： 10.2215/CJN.10361016

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  22 in total

Review 1.  Invited commentary: propensity scores.

Authors:  M M Joffe; P R Rosenbaum
Journal:  Am J Epidemiol       Date:  1999-08-15       Impact factor: 4.897

Review 2.  7. Approaches to Glycemic Treatment.

Authors: 
Journal:  Diabetes Care       Date:  2016-01       Impact factor: 19.112

3.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

Authors:  Amanda I Adler; Richard J Stevens; Sue E Manley; Rudy W Bilous; Carole A Cull; Rury R Holman
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

4.  National trends in treatment of type 2 diabetes mellitus, 1994-2007.

Authors:  G Caleb Alexander; Niraj L Sehgal; Rachael M Moloney; Randall S Stafford
Journal:  Arch Intern Med       Date:  2008-10-27

5.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

6.  Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes.

Authors:  Christianne L Roumie; Robert A Greevy; Carlos G Grijalva; Adriana M Hung; Xulei Liu; Harvey J Murff; Tom A Elasy; Marie R Griffin
Journal:  JAMA       Date:  2014-06-11       Impact factor: 56.272

7.  Kidney disease and increased mortality risk in type 2 diabetes.

Authors:  Maryam Afkarian; Michael C Sachs; Bryan Kestenbaum; Irl B Hirsch; Katherine R Tuttle; Jonathan Himmelfarb; Ian H de Boer
Journal:  J Am Soc Nephrol       Date:  2013-01-29       Impact factor: 10.121

8.  Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase.

Authors:  Anila K Madiraju; Derek M Erion; Yasmeen Rahimi; Xian-Man Zhang; Demetrios T Braddock; Ronald A Albright; Brett J Prigaro; John L Wood; Sanjay Bhanot; Michael J MacDonald; Michael J Jurczak; Joao-Paulo Camporez; Hui-Young Lee; Gary W Cline; Varman T Samuel; Richard G Kibbey; Gerald I Shulman
Journal:  Nature       Date:  2014-05-21       Impact factor: 49.962

9.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079

10.  Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study.

Authors:  Christianne L Roumie; Robert A Greevy; Carlos G Grijalva; Adriana M Hung; Xulei Liu; Marie R Griffin
Journal:  BMC Endocr Disord       Date:  2016-06-02       Impact factor: 2.763
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.